Evaluating Next-Generation BTK Inhibitors

Slides:



Advertisements
Similar presentations
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Advertisements

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Chronic HCV Infection and CKD
The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.
Immunotherapies: Key Considerations in the Identification and Management of irAEs.
Evolving Paradigms in the Management of HR-Positive Breast Cancer
Applying Biosimilars in Hematologic Cancers
Improving Survival in Glioblastoma Multiforme
Advances in Managing Inhibitors in Patients With Hemophilia A
Relapsed/Refractory Follicular Lymphoma Conundrums
Case Studies.
Progression After Cancer Immunotherapy in Advanced NSCLC
Mid-Year Hemophilia Update
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Current and Future Goals in the Treatment of Relapsed CLL
PARP Inhibitors and Cancer: What Do You Need to Know?
Treating Transplant-Ineligible Patients With Multiple Myeloma
BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
The Nurse View.
Addressing Disease Burden in Asthma
The Evolving Role of Immunotherapy in NSCLC
Optimizing Management of Advanced Bladder Cancer
Management Challenges in CLL
Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Next-Gen Psoriasis Therapies:
Management of CMV in HSCT Recipients
Case Studies in Unresectable Hepatocellular Carcinoma
Hyperhidrosis Is Burdensome!
Navigating New Oral Treatment Algorithms in CLL
Targeting BTK Signaling in B-Cell Malignancies
Managing Adverse Events With New Oral Therapies in CLL
Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Ask the Experts.
Optimizing Outcomes and Managing Adverse Events in CLL
Immunotherapy for cSCC
Novel Approaches in T1D Management
Personalized Therapy in Relapsed or Refractory CLL
When Is Biologic Therapy Appropriate for HS?
How to Select Therapy In Newly Diagnosed CLL
Personalizing Management in the Care of Patients With Advanced Sarcoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Parkinson Disease Psychosis
Updates in the Management of Acute Promyelocytic Leukemia
Advances in Immunotherapy for Peanut Allergy
Immune Checkpoint Inhibitors in Lung Cancer
Guide to Atopic Dermatitis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Patient Questions and Expert Answers in Psoriasis:
Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Evaluating BTK Inhibitors in CLL
Managing CLL With BTK Inhibitors
Novel Concepts in the Management of RCC
Debates and Dilemmas, Part 1
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
From Adjuvant to Metastatic in Melanoma
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Checkpoint Inhibitors in First-Line Advanced NSCLC
How to Select Therapy in Relapsed/Refractory CLL
CDK4/6 Inhibitors.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Immune Checkpoint Inhibitors in Lung Cancer
Presentation transcript:

Evaluating Next-Generation BTK Inhibitors

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal

BTK Overview

First-Generation BTK Inhibitor Ibrutinib

Second-Generation BTK Inhibitor Acalabrutinib

Acalabrutinib and Ibrutinib Dosing

Approved Indications Ibrutinib

Ibrutinib in Relapsed CLL Phase 1 Data

Efficacy of Ibrutinib in Other Disease States

Ibrutinib vs Ofatumumab in Previously Treated CLL

Ibrutinib AEs

Challenges With Ibrutinib Use

Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib

Management of Atrial Fibrillation

Managing Infections

Mechanisms of Resistance

Acalabrutinib Pharmacodynamics

Acalabrutinib in Relapsed CLL Results

Acalabrutinib in Relapsed CLL AEs

Acalabrutinib in Relapsed/Refractory MCL

Acalabrutinib in Relapsed/Refractory MCL AEs

Management of Acalabrutinib AEs

Acalabrutinib or Ibrutinib?

Guideline Recommendations for Ibrutinib and Acalabrutinib

Second-Generation BTK Inhibitor Pipeline and Other Novel Combinations

Other Novel Combination Trials

Genomic-Driven Ibrutinib Treatment in MCL

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)